Identification of U937(JAK3-M511I) Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor

Mutated JAK3 has been considered a promising target for cancer therapy. Activating mutations of JAK3 are observed in 3.9%–10% of acute myeloid leukemia (AML) patients, but it is unclear whether AML cells are sensitive to JAK3 inhibitors, and no disease-related human AML cell model has been reported....

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Hongfei, Wang, Jie, He, Rui, Yu, Xiuwen, Li, Shan, Huang, Jing, Li, Jie, Tang, Xia, Song, Xiaojuan, Tu, Zhengchao, Zhang, Zhang, Ding, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802890/
https://www.ncbi.nlm.nih.gov/pubmed/35111683
http://dx.doi.org/10.3389/fonc.2021.807200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8802890/
https://www.ncbi.nlm.nih.gov/pubmed/35111683
http://dx.doi.org/10.3389/fonc.2021.807200

Ejemplares similares